ArticleJAMA dermatology2013
Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study.
Article in JAMA dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Survival impact of second primary cutaneous and non-cutaneous melanoma in melanoma survivors.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- A practical nomogram and risk stratification system predicting the cancer-specific survival for patients aged >50 with advanced melanoma.Frontiers in oncology · 2023Article
- Article
- Development and validation of prognostic nomogram in patients with nonmetastatic malignant melanoma: a SEER population-based study.Cancer medicine · 2020Article
- Conjunctival Melanoma with Ipsilateral, Non-Contiguous Eyelid Involvement: A Case Report and Comprehensive Review of the Literature.Ocular oncology and pathology · 2020Article
- Relationship of Chromosome Arm 10q Variants to Occurrence of Multiple Primary Melanoma in the Population-Based Genes, Environment, and Melanoma (GEM) Study.The Journal of investigative dermatology · 2019Article
- Outcomes and Risk Factors in Patients with Multiple Primary Melanomas.The Journal of investigative dermatology · 2019Article
- Multiple Primary Cutaneous Melanomas in a Bulgarian Patient: The Possible Role of One Step Melanoma Surgery (OSMS) As the Most Adequate Treatment Approach!Open access Macedonian journal of medical sciences · 2018Article
- Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011).Journal of the American Academy of Dermatology · 2018Article
- Clinical characteristics and survival of lung cancer patients associated with multiple primary malignancies.PloS one · 2017Article
- Separate Primary Melanomas of the Bulbar Conjunctiva and Eyelid Skin: Clinical Implications of Multiple Primary Melanomas.Ocular oncology and pathology · 2016Article
- Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up.The American surgeon · 2016Article
- Eleven Primary Melanomas, Colon Cancer, and Atypical Nevi in the Same Patient: A Case Report and Literature Review.Case reports in dermatological medicine · 2016Article
- Inherited variation at MC1R and ASIP and association with melanoma-specific survival.International journal of cancer · 2015Article
- Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.JAMA dermatology · 2014Article
- Sun exposure and melanoma survival: a GEM study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
importanceLittle is known about survival after a diagnosis of a second or higher-order (multiple) primary melanoma, and no study has explored survival in a population-based sample that included patients with single primary melanomas (SPMs) and multiple primary melanomas (MPMs) of any stage. Because people with a first primary melanoma are known to have an increased risk of being diagnosed with another, evidence for prognosis is needed.
objectiveTo determine whether survival after diagnosis was better in patients with MPMs than with SPMs, as suggested in a recent study. DESIGN Survival analysis with median follow-up of 7.6 (range, 0.4-10.6) years.
settingThe Genes, Environment, and Melanoma Study enrolled incident cases of melanoma from population-based cancer registries in Australia, Canada, Italy, and the United States. Multiple primary melanomas were ascertained during a longer period than SPM.
participantsTwo thousand three hundred seventy-two patients with SPM and 1206 with MPM. EXPOSURE: Diagnosis with melanoma. MAIN OUTCOMES AND MEASURES: Melanoma-specific fatality hazard ratios (HR) and 95% confidence intervals associated with clinical and pathological characteristics of SPM, MPM, and both in Cox proportional hazards regression models.
resultsMelanoma thickness was the main determinant of fatality (HR for >4 mm, 7.68 [95% CI, 4.46-13.23]); other independent predictors were ulceration, mitoses, and scalp location. After adjustment for these other predictors, we found little difference in fatality between MPM and SPM (HR for MPM relative to SPM, 1.24 [95% CI, 0.91-1.69; P = .18]). Thicker SPM, however, had higher fatality (HR for >4 mm, 13.56 [95% CI, 6.47-28.40]) than thicker MPM (2.93 [1.17-7.30]). CONCLUSIONS AND RELEVANCE: Although overall fatalities due to SPM and MPM were similar, relative fatality for thicker SPM was greater than that for thicker MPM. This finding may offer support for a difference in outcome between patients with SPM and MPM related to factors other than closer surveillance and earlier diagnosis. The better outcomes are worth further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.